Table 3.
Sensitivity, specificity, PPV, NPV, and accuracy in predicting degree of dysplasia in patients with IPMN
| Sensitivity | Specificity | PPV | NPV | Accuracy | |
|---|---|---|---|---|---|
| HGD | |||||
| MPD ≥ 10 mm | 57.1% | 80.0% | 33.3% | 91.4% | 76.6% |
| Jaundice | 14.3% | 82.5% | 12.5% | 84.6% | 72.3% |
| Tuberous enhancement | 42.9% | 80.0% | 27.3% | 88.9% | 74.5% |
| AP | 57.1% | 82.5% | 36.4% | 91.7% | 78.7% |
| IC | |||||
| MPD ≥ 10 mm | 40.0% | 78.4% | 33.3% | 82.9% | 70.2% |
| Jaundice | 50.0% | 91.9% | 62.5% | 87.2% | 83.0% |
| Tuberous enhancement | 30.0% | 78.4% | 27.3% | 80.6% | 68.1% |
| AP | 20.0% | 75.7% | 18.2% | 77.8% | 63.8% |
| Malignant (HGD + IC) | |||||
| MPD ≥ 10 mm | 47.1% | 86.7% | 66.7% | 74.3% | 72.3% |
| Jaundice | 35.3% | 93.3% | 75.0% | 71.8% | 72.3% |
| Tuberous enhancement | 35.3% | 83.3% | 54.5% | 69.4% | 66.0% |
| AP | 35.3% | 83.3% | 54.5% | 69.4% | 66.0% |
| Intestinal epithelial subtype | |||||
| MPD ≥ 10 mm | 55.6% | 81.6% | 41.7% | 88.6% | 76.6% |
| Jaundice | 33.3% | 86.8% | 37.5% | 84.6% | 76.6% |
| Tuberous enhancement | 33.3% | 78.9% | 27.3% | 83.3% | 70.2% |
| AP | 33.3% | 78.9% | 27.3% | 83.3% | 70.2% |
AP: acute pancreatitis; HGD: high grade dysplasia; IC: invasive cancer; IPMN: intraductal papillary mucinous neoplasms; MPD: main pancreatic duct; NPV: negative predictive value; PPV: positive predictive value